(53 days)
Not Found
No
The document explicitly states "Not Found" for mentions of AI, DNN, or ML, and there is no description of training or test sets, which are typical for AI/ML devices.
No
The device is described as an "ophthalmic microsurgical system" used to "facilitate both anterior segment (i.e., cataract) and posterior segment (i.e., vitreoretinal) ophthalmic surgery." This indicates it's a surgical tool, not a device providing direct therapy for a condition.
No
Explanation: The device description states its purpose is to "facilitate both anterior segment (i.e., cataract) and posterior segment (i.e., vitreoretinal) ophthalmic surgery" and lists surgical procedures it performs (e.g., phacoemulsification, vitrectomy). It does not mention diagnosis.
No
The device description clearly outlines a physical surgical system with various functionalities (phacoemulsification, vitrectomy, etc.), indicating it is a hardware-based medical device, not software-only.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections. They are used to provide information for diagnosis, monitoring, or screening.
- Device Function: The AMO Ophthalmic Surgical System is described as a "modular ophthalmic microsurgical system" used for performing surgical procedures on the eye (anterior and posterior segments). It facilitates actions like phacoemulsification, vitrectomy, irrigation/aspiration, etc.
- Lack of Sample Analysis: The description does not mention the device analyzing any samples taken from the patient's body. Its function is to perform surgical interventions on the patient's eye.
Therefore, the device's purpose and operation fall under the category of a surgical device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The AMO Ophthalmic Surgical System is a modular ophthalmic microsurgical system that facilitates both anterior segment (i.e., cataract) and posterior segment (i.e., vitreoretinal) ophthalmic surgery. The posterior segment surgery module is optional. The modular design allows the users to configure the system to meet their surgical requirements.
Product codes (comma separated list FDA assigned to the subject device)
HQC
Device Description
The AMO Ophthalmic Surgical System is a device designed for use in performing anterior segment ophthalmic surgery (cataract) and posterior segment ophthalmic surgery. The device is intended for use in performing phacoemulsification, phacofragmentation, diathermy, irrigation/aspiration, vitrectomy, extrusion and silicone oil injection and extraction.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Eye (anterior and posterior segments)
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Prior to commercialization, safety tests of the AMO Ophthalmic Surgical System will demonstrate compliance with applicable requirements of the following standards: Can/CSA C22.2 No. 601.1-M90, EN60601-1, EN60601-1-1, EN60601-1-2, EN60601-1-4, EN60601-2-2, EN61000-4-2, EN61000-4-3, EN61000-4-4, EN61000-4-5, ISO 10993-1, UL60601-1, ISO 11135, ISO 11137.
All materials coming into contact with the patient or the patient fluid path have been cleared in previous 510(k)s, with the exception of two new materials. A biocompatibility assessment of the two new materials was conducted. The new materials found in one of the disposable modular tubing packs were tested using the tests listed in the table below.
TEST: Medium Eluate Method (MEM) - GLP, RESULT: Non-cytotoxic
TEST: Agar Overlay - Solid Sample - GLP, RESULT: Non-cytotoxic
TEST: Agar Overlay - Normal Saline Extract - GLP, RESULT: Non-cytotoxic
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 886.4670 Phacofragmentation system.
(a)
Identification. A phacofragmentation system is an AC-powered device with a fragmenting needle intended for use in cataract surgery to disrupt a cataract with ultrasound and extract the cataract.(b)
Classification. Class II.
0
AMO Ophthalmic Surgical System Advanced Medical Optics, Inc
7 2006 APR
510k Premarket Notification
SECTION 3 060366 510(k) SUMMARY
This 510(k) summary is being submitted in accordance with the Medical Device Amendments of 1976, the requirements of the Safe Medical Devices Act (SMDA) of 1990 and 21 CFR 807.92.
| The applicant is: | Advanced Medical Optics, Inc
1700 E. St. Andrew Place
P.O. Box 25162
Santa Ana, CA 92799-5162, USA |
|--------------------------------|-------------------------------------------------------------------------------------------------------------|
| The contact person is: | Toni Elliott
Regulatory Affairs Professional
Tel: (614) 834-1204
Fax: (614) 834-1185 |
| Date the Summary was prepared: | February 8, 2006 |
Device that is the subject of this notification: Trade/Proprietary Name:
The AMO Ophthalmic Surgical System Classification Name: Phacofragmentation System
The devices to which substantial equivalence is claimed:
| 510(k) Number | Clearance Date | Device |
|---|---|---|
| K003638 | 02/13/2001 | Mojave Cataract Extraction System |
| (Marketed as the Sovereign Compact Cataract | ||
| Extraction System) | ||
| K911808 | 06/25/1991 | Gemini Ophthalmic Surgery System |
| (Marketed as the Series 20000 Legacy and Accurus | ||
| Ophthalmic Systems) | ||
| K961310 | 06/27/96 | Premiere II Microsurgical System |
| (Marketed as the Millennium Microsurgical | ||
| System) |
DEVICE DESCRIPTION
The AMO Ophthalmic Surgical System is a device designed for use in performing anterior segment ophthalmic surgery (cataract) and posterior segment ophthalmic surgery. The device is intended for use in performing phacoemulsification, phacofragmentation, diathermy, irrigation/aspiration, vitrectomy, extrusion and silicone oil injection and extraction. The materials, basic scientific concepts, physical properties and intended use of the AMO Ophthalmic Surgical System are substantially equivalent to those of the
1
AMO Ophthalmic Surgical System Advanced Medical Optics, Inc
Mojave Cataract Extraction System, the Accurus Ophthalmic Surgical System and the Millennium Microsurgical System.
INDICATIONS FOR USE
The AMO Ophthalmic Surgical System is a modular ophthalmic microsurgical system that facilitates both anterior segment (i.e., cataract) and posterior segment (i.e., vitreoretinal) ophthalmic surgery. The posterior segment surgery module is optional. The modular design allows the users to configure the system to meet their surgical requirements.
TECHNOLOGICAL CHARACTERISTICS OF THE DEVICE
Anterior Segment Surgery Modes
For anterior segment surgical procedures, the System provides the following main modes: diathermy, phacoemulsification, irrigation/aspiration and vitrectomy.
- . The Diathermy (bipolar) mode is used to coagulate blood vessels during a surgical procedure and, in some cases, to coapt the conjunctiva following a procedure.
- The Phacoemulsification mode is used to break up the nucleus of a cataractous . lens, allowing it to be aspirated from the eye through a small incision.
- . The Irrigation/Aspiration mode allows for controlled aspiration of cortical material from the eye, while maintaining intraocular stability by replacing aspirated material with the irrigation solution. Irrigation can be gravity-fed or pressurized. Pressurized irrigation is only available if the posterior segment module is installed.
- . The Vitrectomy mode is used to cut and remove vitreous from the anterior segment of the eye during secondary intraocular lens implantation, following vitreous loss associated with trauma or during primary cataract surgery.
These anterior segment surgery modes are substantially equivalent to the anterior segment surgery modes of the predicate devices.
Posterior Segment Surgery Modes
- . For posterior segment surgical procedures, the System provides the following main modes: vitrectomy, extrusion, silicone oil injection and extraction, linear diathermy and phacofragmentation.
- . The Vitrectomy mode provides vitreous cutting in the posterior segment using a vitrectomy cutter. This enables the surgeon to remove the vitreous for treatment of various posterior segment conditions.
- . The Extrusion mode acts similarly to the Irrigation/Aspiration mode for anterior segment surgery. It provides vacuum and irrigation for removing ocular material
2
from the eye while maintaining intraocular stability during posterior segment surgical procedures. Irrigation can be gravity-fed or pressurized.
- The Linear Diathermy (bipolar) mode provides diathermy (cautery) power proportional to foot pedal activation.
- The Silicone Oil mode is used to infuse silicone oil into (and remove it from) the . posterior segment of the eye to replace fluid lost during vitreoretinal surgical procedures.
- . The Phacofragmentation mode delivers ultrasonic power for the fragmentation of the crystalline lens through a pars plana incision in the posterior segment thereby allowing the material to be more easily aspirated from the eye.
These modes are substantially equivalent to the posterior segment modes of the Accurus and the Millennium.
SUMMARY OF NON-CLINICAL TESTS
Prior to commercialization, safety tests of the AMO Ophthalmic Surgical System will demonstrate compliance with applicable requirements of the following standards:
| Standard / Guideline | Title |
|---|---|
| Can/CSA C22.2 No. 601.1-M90 | Medical Electrical Equipment - Part 1: General Requirement for Safety |
| EN60601-1 | General requirements for safety. Collateral standard. Safety requirements for medical electrical systems. Section 1.1 Collateral standard: Safety requirements for medical electrical systems |
| EN60601-1-1 | Medical electrical equipment. General requirements for safety. Collateral standard. Safety requirements for medical electrical systems. Section 1.1 Collateral standard: Safety requirements for medical electrical systems |
| EN60601-1-2 | Medical electrical equipment. General requirements for safety. Collateral standard. Electromagnetic compatibility. Requirements and tests |
| EN60601-1-4 | Medical electrical equipment. General requirements for safety. Collateral standard. General requirements for programmable electrical medical systems |
| EN60601-2-2 | Medical electrical equipment. Particular requirements for safety. Particular requirements for the safety of high frequency surgical equipment. Part 2-2: Particular requirements for the safety of high frequency surgical equipment |
| EN61000-4-2 | Electromagnetic compatibility (EMC). Testing and measurement techniques. Electrostatic discharge immunity test. Basic EMC publication |
3
AMO Ophthalmic Surgical System Advanced Medical Optics, Inc
510k Premarket Notification
| Standard / Guideline | Title |
|---|---|
| EN61000-4-3 | Electromagnetic compatibility (EMC). Testing and |
| measurement techniques. Radiated, radio-frequency, | |
| electromagnetic field immunity test | |
| EN61000-4-4 | Electromagnetic compatibility (EMC). Testing and |
| measurement techniques. Electrical fast | |
| transient/burst immunity test | |
| EN61000-4-5 | Electromagnetic compatibility (EMC). Testing and |
| measurement techniques. Surge immunity test | |
| ISO 10993-1 | Biological evaluation of medical devices-Part 1: |
| Evaluation and testing | |
| UL60601-1 | Medical Electrical Equipment, Part 1: General |
| Requirements for Safety | |
| ISO 11135 | Advancement of Medical Instrumentation |
| Recommended Practice Guideline “Medical Devices |
- Validation and Routine Control of Ethylene Oxide
Sterilization |
| ISO 11137 | Sterilization of Health Care Product Requirements for
Validation and Routine Control - Radiation
Sterilization |
All materials coming into contact with the patient or the patient fluid path have been cleared in previous 510(k)s, with the exception of two new materials. A biocompatibility assessment of the two new materials was conducted. The new materials found in one of the disposable modular tubing packs were tested using the tests listed in the table below.
| TEST | RESULT |
|---|---|
| Medium Eluate Method (MEM) - GLP | Non-cytotoxic |
| Agar Overlay - Solid Sample - GLP | Non-cytotoxic |
| Agar Overlay - Normal Saline Extract - GLP | Non-cytotoxic |
SUMMARY
The technological characteristics affecting the performance of the System are substantially equivalent to those of the predicate devices previously listed. The AMO Ophthalmic Surgical System will be manufactured in compliance with FDA and ISO quality system requirements. System validation and verification will demonstrate that the functional requirements and system specifications have been met prior to commercial release.
4
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized symbol that resembles three wavy lines or ribbons, which are meant to represent the human form. The logo is black and white.
Public Health Service
7 2006 APR
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Advanced Medical Optics, Inc. c/o Toni D. Elliott Regulatory Affairs Professional 1700 East St. Andrew Place P.O. Box 25162 Santa Ana. CA 92799
Re: K060366
Trade/Device Name: The AMO Ophthalmic Surgical System Regulation Number: 21 CFR 886.4670 Regulation Name: Phacofragmentation system Regulatory Class: Class II Product Code: HQC Dated: February 8, 2006 Received: February 13, 2006
Dear Ms. Elliott:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
5
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 827-8910. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
MBEychus MD
Malvina B. Eydelman, M.D Division Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
SECTION 2
INDICATIONS FOR USE
510(k) Number (if known): Unknown at this time
Device Name: The AMO Ophthalmic Surgical System
Indications for Use:
The AMO Ophthalmic Surgical System is a modular ophthalmic microsurgical system that facilitates both anterior segment (i.e., cataract) and posterior segment (i.e., vitreoretinal) ophthalmic surgery. The posterior segment surgery module is optional. The modular design allows the users to configure the system to meet their surgical requirements.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use _____________________________________________________________________________________________________________________________________________________________
OR
Over-The-Counter Use
(Per 21 CFR 801.109)
(Optional Format 1-2-96)
Dennis L. McCarthy
ohthalmic Ear ose and Throat Devise
510(k) Number K060366